Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic stimulates neuro investments

This article was originally published in The Gray Sheet

Executive Summary

Firm plans to vitalize its neurological and urological therapies business with major investments in clinical trials. At least six trials, including for its Kinetra and Soletra neurostimulation systems to treat depression and obsessive compulsive disorder, are expected to be underway by fall of 2007, Medtronic announced April 24. The studies, some of which will be IDE trials for new or more specific product indications, and all of which will include cost-effectiveness analyses, are intended to bolster efficacy data to spur physician adoption and payor acceptance, said Richard Kuntz, MD, president of Medtronic's neurological business. Kuntz, with clinical trial expertise from the Harvard Clinical Research Institute, was brought on board in October to help Medtronic make headway in the under-penetrated neurostimulation market...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT023502

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel